Urinary Tract Tumor Organoids Reveal Eminent Differences in Drug Sensitivities When Compared to 2-Dimensional Culture Systems
Open Access
- 4 June 2022
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (11) , 6305
Abstract
Generation of organoids from urinary tract tumor samples was pioneered a few years ago. We generated organoids from two upper tract urothelial carcinomas and from one bladder cancer sample, and confirmed the expression of cytokeratins as urothelial antigens, vimentin as a mesenchymal marker, and fibroblast growth factor receptor 3 by immunohistochemistry. We investigated the dose response curves of two novel components, venetoclax versus S63845, in comparison to the clinical standard cisplatin in organoids in comparison to the corresponding two-dimensional cultures. Normal urothelial cells and tumor lines RT4 and HT1197 served as controls. We report that upper tract urothelial carcinoma cells and bladder cancer cells in two-dimensional cultures yielded clearly different sensitivities towards venetoclax, S63845, and cisplatin. Two-dimensional cultures were more sensitive at low drug concentrations, while organoids yielded higher drug efficacies at higher doses. In some two-dimensional cell viability experiments, colorimetric assays yielded different IC50 toxicity levels when compared to chemiluminescence assays. Organoids exhibited distinct sensitivities towards cisplatin and to a somewhat lesser extent towards venetoclax or S63845, respectively, and significantly different sensitivities towards the three drugs investigated when compared to the corresponding two-dimensional cultures. We conclude that organoids maintained inter-individual sensitivities towards venetoclax, S63845, and cisplatin. The preclinical models and test systems employed may bias the results of cytotoxicity studies.Keywords
Funding Information
- California Department of Fish and Game (663952)
This publication has 112 references indexed in Scilit:
- EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013European Urology, 2013
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature, 2012
- Focal adhesion kinase and endothelial cell apoptosisMicrovascular Research, 2012
- Integrin Signaling, Cell Survival, and Anoikis: Distinctions, Differences, and DifferentiationJournal of Signal Transduction, 2011
- International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 TrialJournal of Clinical Oncology, 2011
- Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cellsProceedings of the National Academy of Sciences, 2009
- Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer TherapyClinical Cancer Research, 2009
- Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma CollaborationCancer, 2009
- Cisplatin: mode of cytotoxic action and molecular basis of resistanceOncogene, 2003
- Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cellsOncogene, 2001